Ziv-aflibercept与贝伐珠单抗术前给药在糖尿病玻璃体切除术中的随机对照试验
这项随机对照试验比较了玻璃体腔注射ziv-aflibercept(IVZ)与贝伐珠单抗(IVB)在严重增殖性糖尿病视网膜病变(PDR)患者行平坦部玻璃体切除术(PPV)前的效果。结果显示IVZ组6个月最佳矫正视力(BCVA)更优(p=0.0035)、手术时间更短(p=0.0013)、术后玻璃体出血复发更少(p=0.0101)。
要点
- 术前IVZ较IVB可改善PDR患者PPV术后6个月BCVA。
- IVZ组手术时间更短,术后玻璃体出血复发率更低。
- 两组围术期牵引性视网膜脱离及术中并发症无显著差异。
核心结论
- 对于PDR相关并发症需行PPV的患者,术前IVZ较IVB可获得更好的最终视力、更短的手术时间和更少的术后玻璃体出血复发。
主要发现
- IVZ组6个月BCVA优于IVB组(p=0.0035)。
- IVZ组手术时间短于IVB组(p=0.0013)。
- IVZ组术后玻璃体出血复发率低于IVB组(p=0.0101)。
- 两组在基线特征、围术期牵引性视网膜脱离、术中并发症及6个月内非计划PPV发生率方面无显著差异。
临床怎么用
- 在PDR相关并发症行PPV前,可考虑优先选择IVZ而非IVB以改善术后视力并减少玻璃体出血复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the effectiveness of intravitreal ziv-aflibercept (IVZ) to intravitreal bevacizumab (IVB) administered preoperatively to patients undergoing pars plana vitrectomy (PPV) for severe manifestations of proliferative diabetic retinopathy (PDR). DESIGN: Randomised clinical trial (RCT). METHODS: Two hundred and six patients with PDR-related complications requiring PPV were randomised into one of two treatment groups: Group A received IVZ (1.25 mg/0.05 mL) 1-10 days before PPV, while Group B received IVB (1.25 mg/0.05 mL) 1-10 days before PPV. The primary outcome was best-corrected visual acuity (BCVA) at 6 months follow-up. Secondary outcome measures were perioperative tractional retinal detachment (TRD) rates, surgical times, intraoperative and postoperative complications and incidence of unplanned PPV during the 6 month study interval. RESULTS: One hundred and seventy three subjects underwent PPV and completed the 6-month follow-up interval. Group A subjects had better BCVA at 6 months (p=0.0035), shorter surgical times (p=0.0013) and were less likely to have a recurrence of vitreous haemorrhaging in the postoperative period (p=0.0101) when compared with subjects in Group B. There were no significant differences among the treatment groups with regards to baseline characteristics, perioperative TRD development, intraoperative complications and incidence of unplanned PPV during the 6 month study interval. CONCLUSIONS: This RCT demonstrated better final visual outcomes, shorter operating times and less vitreous haemorrhage recurrences in the postoperative period when subjects received IVZ compared to IVB prior to PPV for the treatment of PDR-related complications.
引用
- Aleman I, Castillo Velazquez J, Rush SW, et al. Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial. Br J Ophthalmol. 2019. PMID: 30705040. doi:10.1136/bjophthalmol-2018-313313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。